title: Ustekinumab for the treatment of psoriatic arthritis: an update.
abstract: Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.
authors.affiliation: Department of Dermatology, University of California, Davis, CA, USA.
authors.forename: Parastoo
authors.initials: P
authors.lastname: Davari
authors.affiliation: Department of Dermatology, University of California, Davis, CA, USA.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Leo
authors.affiliation: Department of Dermatology, University of California, Davis, CA, USA.
authors.forename: Faranak
authors.initials: F
authors.lastname: Kamangar
authors.affiliation: Department of Dermatology, University of California, Davis, CA, USA.
authors.forename: Nasim
authors.initials: N
authors.lastname: Fazel
keywords: psoriasis; psoriatic arthritis; ustekinumab